AZ-1355

Research use only, not for human use.

AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.

AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.

——

AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rat. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice.

——

GPCR/G Protein

Prostaglandin Receptor

Prostaglandin Receptor

——

——

75451-07-9

299.32

C17H17NO4

>98% (HPLC)

——

O(C)C1=C2C(CNC=3C(O2)=CC=C(C(OCC)=O)C3)=CC=C1

——

(-20℃)

With Ice Pack

≥ 2 years